NICE recommends Novartis’ Piqray therapy by John Pinching | Jul 14, 2022 | News | 0 Piqray is a targeted treatment for thousands of advanced breast cancer patients Read More
EU regulators approve Novartis’ breast cancer combo by Selina McKee | Jul 31, 2020 | News | 0 Piqray in combination with fulvestrant is the first treatment for tumours with a PIK3CA mutation Read More
New vaccine for Ebola among CHMP recommendations by Selina McKee | Jun 1, 2020 | News | 0 The vaccine could be Janssen’s first to win EU approval Read More
FDA approval for Novartis’ Piqray by Anna Smith | May 28, 2019 | News | 0 The FDA approval is based on a Phase III trial, SOLAR-1, in which the combination nearly doubled median progression free survival. Read More